A detailed history of Norges Bank transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Norges Bank holds 78,186 shares of VERV stock, worth $501,954. This represents 0.0% of its overall portfolio holdings.

Number of Shares
78,186
Holding current value
$501,954
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

BUY
$4.5 - $7.19 $351,837 - $562,157
78,186 New
78,186 $440,000
Q2 2024

Aug 14, 2024

BUY
$4.76 - $12.79 $372,165 - $999,998
78,186 New
78,186 $381,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $385M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.